Skip to main content

Insmed, Inc. (INSM)

NASDAQ: INSM · IEX Real-Time Price · USD
28.93 -1.68 (-5.49%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap3.42B
Revenue (ttm)173.75M
Net Income (ttm)-423.89M
Shares Out118.37M
EPS (ttm)-3.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume627,401
Open30.57
Previous Close30.61
Day's Range28.29 - 30.46
52-Week Range22.00 - 45.44
Beta2.17
AnalystsStrong Buy
Price Target53.44 (+84.7%)
Earnings DateOct 28, 2021

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr...

IndustryBiotechnology
IPO DateJun 1, 2000
CEOWilliam Lewis
Employees521
Stock ExchangeNASDAQ
Ticker SymbolINSM
Full Company Profile

Financial Performance

In 2020, Insmed's revenue was $164.41 million, an increase of 20.48% compared to the previous year's $136.47 million. Losses were -$294.09 million, 15.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Insmed stock is "Strong Buy." The 12-month stock price forecast is 53.44, which is an increase of 84.72% from the latest price.

Price Target
$53.44
(84.72% upside)
Analyst Consensus: Strong Buy

News

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Nov. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

3 weeks ago - PRNewsWire

Insmed To Participate in Three November Conferences

BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

3 weeks ago - PRNewsWire

New Strong Sell Stocks for October 29th

IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

Other symbols:BSETDVAIBIOPOST
4 weeks ago - Zacks Investment Research

Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021

BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

1 month ago - PRNewsWire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Oct. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

1 month ago - PRNewsWire

Insmed To Participate in Five September Conferences

BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...

2 months ago - PRNewsWire

Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy?

Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -10.59% and 4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update

BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

3 months ago - PRNewsWire

Earnings Preview: Insmed (INSM) Q2 Earnings Expected to Decline

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks

Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul...

4 months ago - Zacks Investment Research

Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021

BRIDGEWATER, N.J., July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

4 months ago - PRNewsWire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., July 8, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

4 months ago - PRNewsWire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

5 months ago - PRNewsWire

Insmed To Present at Two June Conferences

BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

6 months ago - PRNewsWire

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Con...

BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

6 months ago - PRNewsWire

Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underw...

BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering")...

6 months ago - PRNewsWire

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the ...

6 months ago - PRNewsWire

Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million aggre...

6 months ago - PRNewsWire

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 2.20% and 1.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Insmed Reports First Quarter 2021 Financial Results and Provides Business Update

BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...

6 months ago - PRNewsWire

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research